CD8A and neoplasm: This system demonstrated strong antitumor effects in CRC, improving tumour response to anti-PD1 therapy and overcoming resistance to immune checkpoint blockade (ICB) by suppressing MDSC recruitment and enhancing CD8+ T cell infiltration [107].